Posted in | News | Renewable Energy | Wind Power

Arise to Sell Construction-Ready 33MW Mombyåsen Wind Farm to Allianz Capital Partners

Arise AB (publ) (“Arise”), has entered into an agreement with a fund managed by Allianz Capital Partners (ACP), for the sale of the construction-ready 33 MW Mombyåsen wind farm (the “Project”). In addition to the sale, Arise will deliver civil and internal grid works under a turn-key contract as well as manage the construction, and once operational, operate the Project on behalf of ACP through asset management agreements.

As a result Arise estimates to receive revenues under the various contracts relating to the sale and construction phase with a corresponding positive earnings impact of approx. 33 MSEK in 2015 and 2016, combined. Arise will also receive asset management revenues under a 5-year contract after the Project has been commissioned.

Vestas will be supplying 10 Vestas V126 3.3 MW turbines for the Project. Vattenfall will supply the grid connection and Arise will supply the civil and internal grid works which has been subcontracted to among others NCC. Construction of the Project has begun and commissioning is expected during the end of 2016.

Arise secured the project rights to Mombyåsen in 2014 and finally acquired the underlying project rights in May 2015 from E.ON. During this period Arise worked successfully to bring the Project to a construction ready phase and to secure an investor.

“We are delighted to have partnered with Allianz in this project and look forward to working together with such a reputable organization in delivering this project. We are also pleased that this marks the fifth transaction, or a total of 128 MW (of which 98 MW sold), by Arise in a time period of only 9 months, demonstrating our capability to deliver on our strategy as well as the strength of our portfolio and construction & asset management platform”, says Peter Nygren, CEO of Arise.

“We are very pleased to further strengthen our position in the Swedish wind market by acquiring the Mombyåsen project – our fourth wind park in Sweden”, said David Jones, Head of Renewable Energy at Allianz Capital Partners. “We are looking forward to working with both Arise and Vestas to ensure the smooth construction and optimal long-term operation of the asset.”

Halmstad 6 August, 2015 ARISE AB (publ)

The information contained herein constitutes information which Arise AB is legally required to publish under the Swedish Securities Market Act (2007:528) and/or the Swedish Financial Instruments Trading Act (1991:980). The information was released for publication at 1 pm CET on 6 August 2015.

About Arise Arise is one of Sweden´s leading wind power companies, with the business concept to develop, build and manage onshore wind farms for its own account and on behalf of investors. The company is listed on NASDAQ OMX Stockholm. Arise AB (publ), P.O. Box 808, SE-301 18 Halmstad, Sweden, telephone +46 (0)35 20 20 900, corporate id .no. 556274-6726, E-mail [email protected],

About Allianz Capital Partners Allianz Capital Partners is the Allianz Group's in-house investment manager for alternative investments. With offices in Munich, London, New York and Singapore Allianz Capital Partners manages around EUR 12 billion of alternative assets. The investment focus is on direct investments in infrastructure and renewable energy as well as private equity fund investments. ACP’s investment strategy is targeted to generate attractive, long-term and stable returns while diversifying the overall investment portfolio for the Allianz Group insurance companies.

This information was brought to you by Cision

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.